Last reviewed · How we verify
VP16, ATG
VP16 is an alkylating agent that works by cross-linking DNA, thereby inhibiting DNA replication and transcription.
VP16 is an alkylating agent that works by cross-linking DNA, thereby inhibiting DNA replication and transcription. Used for Small cell lung cancer, Testicular cancer, Ovarian cancer.
At a glance
| Generic name | VP16, ATG |
|---|---|
| Also known as | Etoposid, Antithymoglobuline, VP16: Etoposid, ATG: Antithymoglobuline |
| Sponsor | St. Anna Kinderkrebsforschung |
| Drug class | Alkylating agent |
| Target | Topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
VP16, also known as etoposide, is a topoisomerase II inhibitor that induces DNA damage by forming a stable cleavage complex, which leads to DNA strand breaks and ultimately cell death. This mechanism is particularly effective in rapidly dividing cancer cells.
Approved indications
- Small cell lung cancer
- Testicular cancer
- Ovarian cancer
Common side effects
- Myelosuppression
- Nausea and vomiting
- Fatigue
Key clinical trials
- Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases (PHASE2)
- Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (PHASE3)
- A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma (PHASE1, PHASE2)
- Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL (PHASE2, PHASE3)
- Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults (PHASE2)
- Allo-HSCT vs ASCT in Adult T-LBL (NA)
- Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer (PHASE1)
- Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VP16, ATG CI brief — competitive landscape report
- VP16, ATG updates RSS · CI watch RSS
- St. Anna Kinderkrebsforschung portfolio CI